drugset
drugset / Trial / NCT03393962

Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

NCT03393962 ↗

Phase 1/2 Enrolling by invitation 20 enrolled Shenzhen Geno-Immune Medical Institute
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, phase I/II trial to evaluate the safety and efficacy of ovarian cancer-specific, engineered immune effectors (OC-EIEs) in women.

Timeline

Start
2025-12-01
Primary completion
2028-01-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject OC-EIEs Cell therapy 100000 cells/kg Intravenous
Subject OC-EIEs Cell therapy 4e+06 cells/kg Intravenous

Indications

ovarian cancer